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Abstract
Hypoxic gene expression contributes to the pathogenesis of many diseases, including organ 
fibrosis, age-related macular degeneration and cancer. HIF-1, a transcription factor central to the 
hypoxic gene expression, mediates multiple processes including neovascularization, cancer 
metastasis and cell survival. Py-Im polyamide 1 has been shown to inhibit HIF-1-mediated gene 
expression in cell culture but its activity in vivo was unknown. This study reports activity of 
polyamide 1 in subcutaneous tumors capable of mounting a hypoxic response and showing 
neovascularization. We show that 1 distributes into subcutaneous tumor xenografts and normal 
tissues, reduces the expression of proangiogenic and prometastatic factors, inhibits the formation 
of new tumor blood vessels and suppresses tumor growth. Tumors treated with 1 show no increase 
in HIF-1a and have reduced ability to adapt to the hypoxic conditions, as evidenced by increased 
apoptosis in HIF-1a positive regions and the increased proximity of necrotic regions to 
vasculature. Overall, these results show that a molecule designed to block the transcriptional 
activity of HIF-1 has potent anti-tumor activity in vivo, consistent with partial inhibition of the 
tumor hypoxic response.
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Introduction
Oxygen sensing is involved in a range of natural physiological processes such as embryonal 
development, wound healing and immune response (1). However, its dysregulation can 
contribute to pathogenesis of multiple diseases including fibrosis, erythrocythemia, heart 
disease and cancer - a group of diseases leading to nearly 600,000 deaths every year, in the 
United States alone (2). While new cancer treatments are being developed, many of the 
cancer therapies are hampered by presence of low levels of oxygen in tumors (3), known as 
tumor hypoxia, regulated mainly by Hypoxia Inducible Factors (HIFs) (4). Among them - 
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HIF-1 (5) - is a transcription factor that is often is associated with poorer patient survival (3). 
HIF-1 orchestrates numerous aspects of cancer progression - tumor angiogenesis, cell 
survival in hypoxia and metastasis (3, 6, 7). Most inhibitors affect HIF-1 signaling indirectly, 
by targeting other proteins, including Topoisomerase I, mammalian target of rapamycin 
(mTOR) or microtubules (7, 8). Established therapeutic strategies focus on modulating 
HIF-1 signaling by altering the HIF-1 protein levels (8), its dimerization and protein 
interactions (9–11), or its DNA binding and transcriptional activity (12–14).
One method to inhibit transcriptional activity of HIF-1 is to displace it from its DNA-
binding site – HIF-1 responsive elements (HREs), for example by a molecule shown in this 
report (compound 1. Fig. 1A) (12, 13). Compound 1 is a member of a class of DNA-binding 
small molecules – Pyrrole-Imidazole (Py-Im) polyamides - which can be programmed to 
recognize a broad repertoire of sequences with affinities and specificities comparable to 
those of transcription factors (15). We reported that polyamides can modulate gene 
expression driven by many transcription factors in tissue culture (12, 13, 16–18).
Experiments focused on HIF-1-DNA binding inhibition demonstrated the ability of 1 to 
displace the HIF-1 complex from DNA in vitro (12), and by reducing HIF-1a occupancy at 
selected HREs in a common tissue culture model of hypoxic response - U251 cells as 
represented in Fig. 1B (13). When U251 cells were treated with Deferoxamine, an iron 
chelator and HIF-1 activator (19), 1 was capable of inhibiting 23% of the induced genes, 
establishing polyamide 1 as a partial inhibitor of HIF-1 transcriptional activity (13). The 
concentration used was 1 μM, well below what was measured in the tumor tissues 
investigated in this study (2–3.5 μM). The overall gene expression changes included many 
important proangiogenic factors, such as VEGFA, FLT1 or Endothelin-1, but also other 
factors. In light of the recent developments in cancer systems biology (20, 21) the broad 
effects of Py-Im polyamides on gene expression 1 (13, 16–18) led us to posit that their 
effects may arise due to affecting multiple targets. Recent discoveries show that drugs 
commonly act upon multiple molecular entities (20, 21) and this feature could be beneficial 
in cancer treatment thanks to decreased likelihood of developing drug resistance (22). 
However the potential for toxicity due to off target effects is a point of concern. Our 
mechanistic investigations expanded beyond the transcription factor:DNA interface and 
found that Py-Im polyamides can induce degradation of the large subunit of RNA 
polymerase II, activation of the P53 stress response without concurrent DNA damage (23) 
and induction of DNA replication stress (24).
We decided to establish whether the pattern of gene expression caused by administration of a 
Py-Im polyamide binding DNA sequence found in HREs (5′-WTWCG-3′) could result in 
measurable and useful anti-tumor effects in vivo. Our experiments focused on suppression of 
the phenotypes typical for tumor hypoxia, such as tumor vascularization, hypoxic gene 
expression or cancer cell survival (1, 8). We chose a subcutaneous tumor model, due to its 
hypoxic nature (3) and reliability of these measurements. The cell lines chosen for 
engraftment have been evaluated extensively in xenograft models of cancer (25, 26) and 
hypoxic gene expression in one of them (U251) can be regulated by 1 (13), making it a good 
choice for evaluating in vivo mechanism of action of 1. The second cell line, GBM39 (27), 
was derived from the same site as U251 cells (brain), but was maintained as subcutaneous 
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xenografts and expanded in serum-free conditions as spheroids. The serum-free treatment 
maintains genetic and histologic variability of human tumors and was thus our choice to test 
generality of mechanism of action of polyamide 1 (28). Our previous in vivo investigations 
demonstrated the bioavailability of various Py-Im polyamides upon intravenous (29), 
intraperitoneal and subcutaneous administration (30). Subsequent in vivo xenograft studies 
established that polyamides could accumulate in subcutaneously grafted tumors (18, 30, 31), 
modulate tumor gene expression (18, 30) and inhibit growth of prostate cancer xenografts 
(23, 32). The distinct profile of gene expression modulation, favorable pharmacokinetics and 
ability to modulate all of the tested aspects of hypoxic response by 1, could establish it as an 
interesting candidate for treatment of cancer and other hypoxia-related diseases. In the 
current study we established the ability of Py-Im polyamide 1 to interfere with hypoxic 
response, regulate gene expression in tumors and to inhibit tumor growth and angiogenesis.
Materials and methods
Cell Maintenance
U251 cell line was a kind gift of Dr. Giovanni Mellilo (NCI) in 2005. GBM39 cells were a 
gift of Dr. David Akhavan (UCLA) in 2013, originally obtained from Prof. David James 
(UCSF). The cell lines were authenticated using StemElite ID assay (Laragen). U251 cells 
were maintained in RPMI-1640 medium supplemented with 10% FBS. GBM39 cells were 
cultured in suspension in F12/DMEM medium supplemented with b27, EGF (20 ng/ml) , 
FGF2 (20ng/ml), and Glutamax, heparin (50 μg/ml), with growth factors replaced every two 
days. After 25 passages GBM39 were reestablished as subcutaneous xenografts (NSG mice). 
The tumor was disintegrated, digested in 10% accutase (3 h), cells resuspended by pipetting 
and then cultured as described above. Human umbilical vein endothelial cells (HUVECs) 
were cultured in 200 PRF medium (Gibco) supplemented with Low Serum Growth 
Supplement (LSGS, Invitrogen). Media was exchanged every 48 h and cells passaged 
weekly.
Tube formation assay
HUVECs were plated at 2×105 cells (75cm flask). After 36 hours, compound 1 (5 μM) was 
added for 72 h. Twelve-well plates were coated with 100 μl/well Geltrex (Invitrogen) and 
allowed to solidify at 37°C for 60 min. Cells were trypsinized and resuspended in 200 PRF 
medium at 2×105 mL−1, and plated in the 12-well plates at 400 μL per well. After 6–12 
hours the wells were imaged on an inverted microscope by selecting 4 random fields of 
view.
Pharmacokinetic and toxicity experiments
Animal experiments were carried out according to approved Institutional Animal Care and 
Use Committee protocols at the California Institute of Technology (Pasadena, CA). PK 
studies were done as previously described (30). Serum for analysis of toxicity markers 
(IDEXX) was obtained by RO collection and centrifugation (2000g, 15 min) in Serum 
Separator Tubes (BD Biosciences). The radioquantitation of 2 was performed as described 
elsewhere (33).
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Immunohistochemistry and histologic analysis
Tissue processing was conducted at the Tissue Processing Core Laboratory (TPCL) at 
UCLA, using 5 μm paraffin sections. Tumor microvessels were visualized using anti-mouse 
CD31 staining using SC-1506 antibody (SCBT), apoptosis was assayed for using anti-
human Cleaved-Caspase-3 (CC3) antibody (9664, CellSignal) and HIF-1a using CME 349A 
(Biocare Medical). At least two tissue sections per slide were used for each experiment. 
Slides were scanned using an Aperio ScanScope AT (Aperio) and positive pixel 
measurements were done using Imagescope software.
Perinecrotic area was defined as a field of view at 20× magnification that contained 50% 
necrosis and 50% adjacent, non-necrotic area, with edge of necrosis in the middle of the 
screen. Number of histologic measurements for each tissue section were chosen to limit 
variability of the final average value to <10%, per tumor, or until all available data in the 
section was counted. Ki-67 measurements were done using Immunoratio software at 20× 
magnification, with n=24 per tumor section. Nuclear density (and by proxy – necrosis) was 
assessed by automatic nuclei counting using Image-based Tool for Counting Nuclei (ITCN), 
16 fields of view were analyzed per tumor section.
At least 6 (CC3), 9 (CD31), or 3 (TUNEL, GBM39), 5 (TUNEL, U251), or 8 (HIF) fields of 
view per tumor chosen randomly prior to analysis, at either 20× (CC3 staining, CD31 
staining for U251, GBM39, Schedules A and B, TUNEL, HIF) or 40× magnification (CD31 
staining for GBM39, Schedule C, due to higher CD31 positive vessel counts). For analysis 
of frequency of apoptotic blood vessels (CC3/CD31 double staining), we counted enough 
high power fields (20x) containing CD31 positive vessels, to assess at least 600 microvessels 
per condition.
Perinecrotic MVD was measured by first delineating nuclei on the edge of necrosis, and then 
offsetting the obtained path by an equivalent of 50 μm-350 μm in Illustrator CS5 (Adobe). 
The MVD was then counted manually for each 50 μm-zone and area integrated in Photoshop 
CS5 (Adobe). At least 40 measurements per tumor were obtained. Measurements of the 
nearest blood vessel-necrosis distance were done manually using Imagescope at 40× 
magnification.
Xenograft experiments
Experiments were carried out in 8–12 week old male NSG mice (NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ, JAX). Cells were injected s.c. into a flank area (2.5×106 of U251 and 
7.5×105 of GBM39 cells). U251 cells were administered in RPMI-1640 medium and 
GBM39 cells in 50% matrigel/culture medium. Before treatment, each vehicle-treated 
control xenograft was paired with a xenograft of the same initial volume to be treated with 1. 
Compound was administered s.c. interscapularly in 20% DMSO/PBS. Mice were weighted 
weekly and euthanized if 15% weight loss, or more was observed.
Quantitative Real Time-Reverse Transcription-PCR assay
Primers (Supplementary Table 1) were designed using Harvard Primer bank (34). The total 
mRNA in tumors was processed as in our previous studies (30).
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RNA-sequencing analysis
Cells for gene expression analysis were plated in 6-well plates at 5–10 × 104 cells per well 
and incubated in RPMI-1640 medium with 10% FBS until ~50% confluence (24–48 h). 
Afterward, medium was exchanged with the growth medium supplemented with 1 (1 μM). 
After 48 hours, either 300 μM of DFO, or PBS was supplemented, cells were incubated for 
an additional 16 hours. The RNA was then harvested using an RNEasy Kit (Qiagen) and 
treated with a Riboguard RNAse inhibitor and TurboDNA Free DNAse (Ambion), according 
to manufacturers' instructions. RNA-Seq libraries were prepared using standard Illumina 
reagents and protocols. Single read sequencing with the read length of 50 nucleotides was 
conducted on the Illumina HiSeq2000 sequencer, producing 35 to 40 million reads per 
library, with a total of three biological replicates per sample. Sequencing data were mapped 
against the combined human (hg19) transcriptome, using the Tophat2 program package 
2.0.13 (35) and the GRCh37 annotation. Differential gene expression was calculated with 
the DEseq2 module (36). Clustering analysis was performed using Cluster 3.0 software (37).
Statistical analysis
Each sample was analyzed using a two-tailed, student’s t-test, assuming normality and 
unequal variance. P-value of 0.05 or less was considered statistically significant.
Results
Activity of Py-Im polyamide 1 depends on the HIF-1a activation
Our previous results showed that 1 can act as an inhibitor of HIF-1-driven gene expression 
(13) in U251 cells. However, we did not determine activity of 1 in cells without HIF-1a 
induction. Tumors contain both hypoxic and normoxic regions and thus it is important to 
establish how 1 acts in cells with and without induced HIF-1a. To address this question, 
U251 cells were first treated with 1 (1 μM, 48 h) or PBS (vehicle). Half of the samples were 
then dosed with a HIF-1a inducer Deferoxamine (DFO, 300 μM, 16 h), while the other half 
with PBS (Supplementary Figure 1A). Their mRNA was then analyzed by RNA-sequencing. 
Gene expression differences for each sample were obtained by normalizing a polyamide-
treated sample with the appropriate non-treated control – cells treated with PBS and 1 were 
normalized to cells treated with PBS only (PBS vs 1), and cells treated with both 1 and DFO 
to cells treated with DFO (DFO vs DFO+1). When 1 was dosed into cells treated with DFO, 
we observed it downregulated 744 genes. When 1 was dosed into cells dosed with PBS, a 
different set of genes was regulated. In fact only 101 out of 723 regulated genes were 
identical for both conditions (14%, Fig. 1C, D). The upregulated genes also varied between 
the two groups. Cells treated with 1 and DFO showed upregulation of 316 genes, while the 
same cells treated with 1 and PBS – 1514 genes. Few genes were in common between the 
two groups (6% for DFO, 1.3% for PBS, Fig. 1C, D). Overall, 17% DFO-induced genes 
were downregulated by 1 at least 2-fold (p < 0.05). Gene clustering analysis suggested 1 
acted to reverse effects of DFO (Supplementary Figure 1B–C). Fewer genes were affected 
by compound 3 at the same dose (Supplementary Figure 1D). Interestingly, we found that 
among the genes that were changed significantly both by 1 (in DFO-induced cells) and by 
DFO, the Py-Im polyamide 1 inhibited DFO-induced gene expression in 96% of the genes 
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(2557 out of 2661 genes, Supplementary Figure 1E). This indicates that gene expression 
changes caused by DFO, are either unaffected, or reversed by 1, but rarely, if ever, 
exacerbated by treatment with 1.
Py-Im polyamide 1 shows favorable preliminary pharmacokinetics and tissue distribution 
at tolerable doses
In order to evaluate bioavailability of 1 in vivo, we injected it subcutaneously (s.c.) at 6.8 
mg/kg into C57BL6 mice. Compound 1 reached a serum concentration of 11.3±1.6 μM 
within 1.5 h and 7.8±0.4 μM at 4 h post-injection (n=4, Fig. 2A). The radiolabeled analogue 
of 1, Py-Im polyamide 2, was injected intraperitoneally (IP) to quantitate whole-organ 
compound concentrations (n=6, Supplementary Figure 2A, B) into immunocompromised 
NSG mice bearing GBM39 tumors. After 24 h, concentrations of 2 were measured in 
GBM39 xenografts (2.0 μM), host’s kidney (6.3 μM), liver (4.2 μM) and lung (3.1 μM; 
Supplementary Figure 2A). Following 3 injections (6.8 mg/kg s.c., every other day × 3, 
harvest 24h post last injection), all tested tissues showed compound accumulation 
(Supplementary Figure 2B). The same administration of 3 (FITC-conjugate of 1) in NSG 
mice resulted in readily detectable nuclear staining in tumor cells and tested tissue sections 
(Supplementary Figure 2C–E). The nuclear staining was also present when tested in unfixed 
cells in tissue culture setting (Fig. 2B). A single-injection toxicity test showed that 1 did not 
affect animal weight, or levels of serum toxicity markers (ALT, AST, TBIL, BUN, 
Creatinine) at concentrations up to 10 mg/kg (Supplementary Figure 3A, B). Taken together, 
these results supported evaluation of anti-tumor effects of 1 in vivo.
Polyamide 1 suppresses tumor growth in subcutaneous xenografts
To test whether previously established partial inhibition of HIF-1-driven gene expression by 
1 (13) would result in decrease in tumor growth, we engrafted U251 and GBM39 cells s.c. 
into NOD/SCID-γ (NSG) mice. We established three dosing regiments (Supplementary 
Figure 4A) for 1 – Schedule A, consisting of three s.c. injections every other day at 
maximum tolerated dose (6.8 mg/kg, 8 days) and Schedules B and C, with lower dose 
(4.5mg/kg, 3 inj./week) designed for prolonged treatment with low weight loss (<10%) over 
4 weeks (U251 tumors) or 6 weeks (GBM39 tumors). The Schedule A was designed to elicit 
maximum response over a short period of time at a dose tolerable to animals. The Schedules 
B and C were introduced to assess if the compound 1 could retain its activity at a dose that 
could be tolerated over longer periods of time. In all cases, the tumors were harvested 72 h 
after last injection, due to our previous research, indicating that Py-Im polyamide-induced 
apoptosis occurs between 48–72 hours after compound administration in tissue culture 
studies (24).
Mice bearing U251 tumors were subjected to treatment with 1 (Schedule A) which resulted 
in a reduction in median tumor mass (1.8-fold, p<0.013; n=7, 8 for vehicle and treated 
groups; Fig. 2C) compared to vehicle. Similarly, prolonged treatment (Schedule B) resulted 
in 1.9-fold lower median U251 tumor mass (p<0.0125; n=10 per condition; Fig. 2D). 
Consistent results were obtained with a primary glioma cell line (GBM39) xenograft. 
Treatment according to Schedule A resulted in 1.8-fold lower median mass (p<0.016; n=11 
per condition; Supplementary Figure 4B) and prolonged treatment (Schedule C) in 1.6-fold 
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reduction (p<0.041; n=6 per condition; Supplementary Figure 4C). The treatments resulted 
in minor mouse weight loss; the effects were less severe (<5% average w.l. throughout the 
experiment) for schedules B and C (Supplementary Figure 5).
Polyamide 1 reduces microvessels density in xenografts, without inducing endothelial 
apoptosis
Hypoxic signaling is a major driver for angiogenesis and its inhibition leads to decrease in 
microvessel density (MVD) (1, 8). We measured MVD using anti-mouse CD31 
immunostaining of tumor sections. We observed a significant reduction of MVD in all tested 
scenarios. For U251 tumors, with mice subjected to Schedule A, we observed a 1.4-fold 
median reduction of MVD (p<0.014; n=7, 8 for vehicle and treated groups; Fig. 2E) and 1.7-
fold median decrease for Schedule B (p<0.05; n=10 per condition; Fig. 2F). For GBM39 
tumors, both treatment schedules (A and C) led to 1.4-fold reduction in MVD (p <0.01; 
n=11 and n=6 for Schedules A and C; Supplementary Figure 6A–B).
The decrease in MVD could be caused by direct effect of 1 on the endothelium, for example, 
rendering it either apoptotic, or unable to form blood vessels. We evaluated endothelial 
apoptosis by double-staining of mouse-specific CD31 and Cleaved Caspase-3 (CC3) in 
GBM39 tumors (Schedule C; n=5 tumors, approximately 600 microvessels per condition; 
Fig. 2G). We found no significant endothelial apoptosis in either of the treatment groups. To 
measure angiogenic functionality of endothelium we used in vitro matrigel tube formation 
assay with Human Umbilical Cord Endothelial Cells (HUVEC), revealing 1 (5 μM, 48 h) 
had no effect on tube formation (n=3, Fig. 2H).
Antiangiogenic effects of 1 are associated with inhibition of hypoxic response
Decrease in MVD, without endothelial apoptosis or dysfunction, suggests 1 could interfere 
with the hypoxic response (5). To further test this hypothesis we evaluated other aspects 
affected by hypoxic response, such as tumor cell proliferation (38), apoptosis in HIF-1 
positive, perinecrotic areas (38), nuclear HIF-1a protein accumulation and cell survival in 
areas distant from blood vessels (39, 40). To analyze this, we divided the tumor sections into 
three areas: necrotic, non-necrotic and perinecrotic (Fig. 3A). The non-necrotic areas contain 
nucleated cells with intact cell membranes, while necrotic areas are show loss of nuclei and 
fragmentation of cells. The perinecrotic area represents field of view (20× magnification) 
that contains 50% of cells containing nuclei and 50% of necrotic areas.
Antiangiogenic therapy increases hypoxia in tumors and often leads to decreased 
proliferation (39, 41). Upon treatment with 1 (Schedule B), we observed a 1.2-fold decrease 
(P<0.05; n=10 per condition; Fig. 3B) in proliferation marker (Ki-67) in non-necrotic areas 
of the U251 tumors.
Another effect of induction of hypoxic response is accumulation of HIF-1a (1). However, 
treatment with 1 did not lead to increase in levels of HIF-1a in either U251 (Fig. 3C, D) or 
GBM39 (Supplementary Figure 7A, B) tumors. Lack of HIF-1a accumulation is unlikely to 
be caused by its increased degradation, as 1 does not affect HIF-1a levels in tissue culture 
(Supplementary Figure 7C). Overall, we observed a spatial distribution of HIF-1a in U251 
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tumor sections – perinecrotic areas showed higher HIF-1a levels compared to non-necrotic 
areas (1.8-fold average increase for 1, p<0.001; n=10 per condition; Fig. 3C, D).
Induction of hypoxic signaling can lead to apoptosis resistance in cancer cells (39). 
However, treatment with 1 increased apoptosis significantly in perinecrotic, HIF-1a positive, 
areas (CC3 staining, 1.8-fold, p<0.0012; n=10 per condition; Fig. 3E;). The apoptosis was 
absent in non-necrotic regions of U251 tumors regardless of the treatment (Fig. 3F), 
suggesting 1 is toxic specifically to hypoxic cells. Similarly, TUNEL staining revealed 
convergent results – no increase in apoptotic cells in non-necrotic regions, and 1.7-fold 
(p<0.009, n=10 per condition) increase in apoptosis in perinecrotic tumor regions upon 
treatment with 1 (Supplementary Figure 7D–E). The GBM39 tumors harvested before they 
developed necrosis also revealed no induction of apoptosis by 1 (Supplementary Figure 7F).
Hypoxic signaling mediates cell survival in areas with low oxygen pressures. With 
increasing distance to blood vessels, tumor necrosis appears as a result of the death of cells 
with inadequate oxygen supply (1, 42). The oxygen pressure decreases as the function of 
distance from blood vessels, and typically does not reach beyond approximately 200 μm. 
Cells adapt to low oxygen pressures by activating hypoxic signaling, and once oxygen 
pressures drop below a critical value, cell necrosis occurs (1, 42). The cells that succeed to 
survive at distances comparable to 200 μm from blood vessels, can thus be deemed as having 
a functional hypoxic response. Impairment of hypoxic signaling will result in necrosis 
occurring at higher oxygen pressures – at shorter distances from blood vessels. Therefore to 
measure if 1 decreases ability of cells to adapt to low oxygen pressures, we measured MVD 
as a function of distance from the edge of necrotic areas. We found the expected lack of 
microvessels near necrotic edges (<100 μm). In tumors derived from animals treated with 1 
(U251, Schedule B) necrotic edge appeared closer to the blood vessels. The median 
distances between the edge of necrosis and the nearest blood vessels, were significantly 
shorter for both U251 and GBM39 tumors treated with 1, as compared to vehicle-treated 
controls (p<0.01, Supplementary Figure 7G). Similarly, at short distances around necrosis 
the mean MVD appeared higher for tumors treated with 1, suggesting treated tumor cells 
require higher level of nutrients and oxygen for survival (3.3-fold at 150 μm and 2.3-fold for 
200 μm distance from the necrotic edge, p<0.02 and p<0.01; Fig. 4A, B).
Lower MVD and lower cell survival at a distance from blood vessels, should lead to an 
increase in necrotic area. However, the complex pattern of necrosis (micronecroses) in U251 
tumors made it difficult to quantify it by a simple delineation. Instead, we decided to 
automatically count nuclei in the whole tumor section and found lower nuclear density in 
tumors treated with 1, (10% fewer nuclei, p<0.03, Supplementary Figure 8A). The further 
evidence of necrosis induction by 1, was present after short-term treatment with 1 in 
GBM39 tumors (Schedule A) where transient accumulation of HIF-1a (Supplementary 
Figure 8B–D) led to presence of necrosis (Supplementary Figure 8E), specifically localized 
to HIF-1a positive areas that were distant from microvessels (Supplementary Figure 8E, F).
Overall, compound 1 decreases proliferation and nuclear density, selectively induces 
apoptosis in perinecrotic, HIF-1a positive areas, and causes necrotic areas to appear in 
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proximity of blood vessels despite the presence of a blood supply, but treatment does not 
result in long-term HIF-1a accumulation.
Py-Im polyamide 1 reduces expression of proangiogenic and prometastatic factors in vivo
A common adverse effect of antiangiogenic treatment is upregulation of proangiogenic and 
prometastatic gene expression which renders the antiangiogenic therapies less effective and 
is often a result of hypoxic signaling (43). We decided to test if 1 affected mRNA expression 
of such factors in vivo. NSG mice bearing U251 tumors were treated with 1 according to 
Schedule D (6.8 mg/kg, 2 inj., on days 1 and 3; tumors harvested on day 5; SI 
Supplementary Figure 4A). Out of 10 tested proangiogenic factors, four transcripts had 
lower relative expression after treatment with 1 (Fig. 5A), and one (VEGFA) was 
upregulated (1.4-fold) in both mRNA (Fig. 5B) and serum protein levels (Fig. 5C). 
Downregulation of mRNA expression was also apparent in the panel of prometastatic genes. 
Overall, 5 out of 6 tested transcripts were downregulated in the group treated with 1 (Fig. 
5D). The factors significantly affected by 1, included: FLT1, NLGN1, HOXB9, NEDD9, 
MMP2 and MMP14. Interestingly, the mouse receptor of Angiopoietin, Tek, was also 
downregulated. Results for all tested genes can be found in Supplementary Table 2.
Discussion
Regulation of hypoxic signaling is central to maintaining balance between health and 
disease. Its principal regulator - HIF-1 - is essential for tumor initiation and progression, e.g. 
vascularization, cell survival and metastasis (3, 44). Inhibition of HIF-1 activity has 
suppressed tumor progression and reduced cancer resistance to available therapies (reviewed 
in (1, 3)). Our group has previously reported on the function of an HRE-binding Py-Im 
polyamide 1 as a partial inhibitor of HIF-1 dependent transcription in tissue culture (13). 
However, the in vivo activity and mechanism of 1 remained to be explored. We used Py-Im 
polyamide 1 (Fig. 1) to show its activity is dependent on HIF-1a activation (Fig. 1), that it 
inhibits tumor growth, angiogenesis (Fig. 2) and the tested aspects of hypoxic response in 
vivo (Figs. 3 and 4), including inhibition of tumor-derived mRNA expression of 
proangiogenic and prometastatic factors that are often upregulated in hypoxic conditions 
(Fig. 5). We found that the effects of 1 are consistent with what would be expected in case of 
a partial inhibition of hypoxic response (Fig. 6).
Polyamide tissue distribution and preliminary pharmacokinetics
Subcutaneous administration revealed 1 distributes into serum within 1.5 h post-injection, 
with 31% drop in concentration 2.5 h later, indicating multi-hour long half-life. Even though 
1 had favorable pharmacokinetics, its activity in vivo is likely dependent on the target tissue 
concentration. After three intraperitoneal injections (Schedule A), the radioactive analog 2 
reached a concentration of 3.5 μM in GBM39 tumor and higher levels in other tissues. 
Concentrations attained for 1 in all tested tissues were thus higher than used in our tissue 
culture studies (13).
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Effects on tumor growth and vascularization
In the present study, inhibition of tumor growth and reduction in MVD was observed in two 
different cell types in response to treatment with 1. The extent of these effects was 
comparable to ones exerted by Bevacizumab (45) in xenografts derived from U251 (41) and 
GBM39 cells (26). Investigation of possible mechanisms of antiangiogenic action showed 
lack of apoptosis in blood vessel lining, and no measurable influence on tube formation on 
matrigel. Lack of direct effects of 1 on endothelial cells suggests blood vessel recruitment 
might be impaired. One possible explanation is inhibition of expression of tumor-associated 
proangiogenic factors by 1. However, systemic concentration of those proteins could also be 
affected.
Effects on apoptosis, proliferation and HIF-1a levels
Compound 1 induces apoptosis selectively, in HIF-1a-positive, perinecrotic areas. This 
suggests 1 sensitizes cancer cells to hypoxia, which could occur by hypoxic response 
inhibition (3). Our RNA-sequencing data shows that activity of 1 depends on activation of 
HIF-1a, which provides a possible explanation why activity of 1 was restricted to cells in 
HIF-1a positive areas. Further support of this hypothesis is the lack of increase of HIF-1a 
positive cells in the tumors treated according to Schedule B and C. Since 1 did not affect 
HIF-1a levels in U251 cells in tissue culture, it is likely that numbers of HIF-1a positive 
cells were reduced as they went through apoptosis. Finally, increased reliance of cancer cells 
on proximity to vasculature once again suggests their hindered ability to adapt to low partial 
oxygen pressures, which is the main function of the hypoxic response. It is worth noting 
that, despite the fact that more blood vessels exist in proximity of necrosis, the perinecrotic 
areas are not representative of the whole tumor. These areas contain only a small fraction of 
tumor area and inherently contain few blood vessels, which leads to necrosis. The transient 
induction of HIF-1a levels in briefly-treated GBM39 tumors indicates a likely increase in 
tumor hypoxia, or a change in HIF-1a protein levels by direct action of 1. The latter 
possibility is unlikely as 1 had no effect on HIF-1a levels in tissue culture. The apparent 
disparity in HIF-1a levels between the GBM39 tumors treated according to Schedule A, and 
other regimens, could be due to two factors: concentration of 1 was insufficient to induce 
apoptosis of tumor cells in Schedule A, or overall level of hypoxia in these smaller tumors 
(Supplementary Figure 8C) was too low to induce sensitivity to 1. The latter hypothesis is 
supported by comparable HIF-1a levels in non-necrotic regions of GBM39 tumors from a 
group treated according to Schedule C (Supplementary Figure 7A) and by tendency of 
smaller tumors to be less hypoxic (46). Reduced proliferation upon treatment with 1 is likely 
a combination of both reduced MVD and a direct effect of 1 on cancer cells. The former 
hypothesis is supported by the dependence of proliferation on distance from necrosis, while 
the latter – by a reduction in Ki-67 in non-necrotic areas that are presumably sufficiently 
vascularized for unrestricted cell division.
Effects on gene expression
Compound 1 reduced mRNA expression of a panel of genes involved in angiogenesis and 
metastasis. Many of the affected genes carry important functions in tumor adaptation to 
hypoxia – for example Platelet-derived growth factor subunit B (PDGFB) and 
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Angiopoietin-1 (ANGPT1) are involved in blood vessel maturation (43), whereas Lysyl 
Oxidase (LOX) or RHOC were involved in metastasis (47, 48). Other factors significantly 
affected by 1, included: FLT1, NLGN1, HOXB9, NEDD9, MMP2 and MMP14, and a 
mouse Angiopoietin receptor, Tek. We also observed a slight elevation (1.4-fold) in both 
mRNA expression and serum concentration of VEGFA, despite a visible downregulation in 
tissue culture (13). Reduction in microvessel density typically leads to decreased oxygen 
pressure and increased expression of proangiogenic factors, including VEGFA (41, 43). 
Interestingly, recent studies show that regulation of VEGFA activity can be HIF-1-
independent (49, 50). However, it is also possible that VEGFA expression would be higher 
had it not been for treatment with 1. Importantly, elevated expression of VEGFA did not 
prevent 1 from exerting antiangiogenic effect, suggesting its mechanism of action could be 
VEGF-independent.
Conclusions
In summary, this study demonstrates that Py-Im polyamide 1 interferes with the tested 
endpoints of hypoxic response in tumors: it inhibits prometastatic and proangiogenic gene 
expression, induces tumor cell apoptosis selectively in HIF-1a positive areas and decreases 
nuclear density, proliferative index and microvessel density of tumors. The RNA-sequencing 
data revealed that 1 regulates genes differentially in cells with induced and basal levels of 
HIF-1a, providing a potential explanation for selective induction of apoptosis in HIF-1a 
positive cells. This compound could be useful in treatment of hypoxia-related disease as it 
distributes to tissues, has favorable pharmacokinetics, and antitumor and antiangiogenic 
activity in two different xenografts.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Chemical structure and biological activity of Py-Im polyamides binding HRE sequence
A) Chemical structures and ball-and-stick representation of the Py-Im polyamides 1–3. N-
methyl-pyrrole, N-methyl-imidazole and chlorothiophene are represented as open circles, 
filled circles and squares, respectively. B) Our previous studies (13) indicated that compound 
1 can bind to HRE-containing sequence with sub-nanomolar (ka > 1010) affinity and displace 
HIF-1 complex from VEGFA and CA9 promoters in U251 cells in Chromatin Immuno-
Precipitation assay (ChIP). C) Gene expression regulation by 1 (1 μM) in U251 cells with 
elevated levels of HIF-1a (treatment with 300 μM Deferoxamine (DFO)) or native levels of 
HIF-1a (PBS treatment). Cells were treated either with PBS or 1 for 48 hours, and then with 
either PBS or DFO for 16 hours. Gene expression changes for each sample were obtained by 
normalizing a polyamide-treated sample with the appropriate non-treated control – cells 
treated with PBS and 1 were normalized to cells treated with PBS only, and cells treated 
with both 1 and DFO were normalized to cells treated with DFO. Overall, 1 regulates 
expression of a distinct set of genes when cells are co-treated with DFO and 1. D) 
Hierarchical clustering (Euclidian distance, complete linkage) of genes changed at least 
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three-fold as compared to the state untreated with 1. Gene expression changes expressed as 
Log2 values. Three biological replicates were analyzed.
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Figure 2. Polyamide 1 inhibits tumor growth and vascularization after systemic administration
A) Serum concentration of 1 after subcutaneous injection. The C57BL6 mice were injected 
with 1 subcutaneously into interscapular area, after which we drew blood via retroorbital 
collection (n=4 per time point). B) Nuclear uptake of 3 in U251 cells, counterstained with a 
DNA-binding Hoechst 33342 fluorophore. C) Final masses and growth curve of s.c. U251 
xenografts derived from animals subjected to Schedule A (n=7,8, for vehicle and treated 
groups; for volumes, measurements at the 3rd an 5th day contain 5 data points.) D) Final 
masses and growth curve of U251 xenografts (Schedule B, n=10 per condition). E) Mice 
harboring xenografts were treated with 1 according to Schedule A and their MVD score was 
measured using anti-mouse CD31 immunostaining of tumor sections (For U251 n=7,8 for 
vehicle, and treated groups). F) Prolonged treatments, according to Schedule B in U251 
xenografts led to comparable decrease in MVD. G) Apoptosis in blood vessels was 
determined by double-staining of Cleaved Caspase-3 (CC3) and mouse CD31 of GBM39 
tumor sections treated according to Schedule C. Both vehicle and polyamide-1 treated 
samples exhibited low levels of blood vessel apoptosis and the differences between the 
groups were not significant (p=0.37, n=5 per condition). H) An in vitro angiogenesis assay - 
matrigel tube formation assay using HUVECs - shows treatment with 1 (5 μM) over 48h has 
no effect on endothelial tube formation. Arrows denote injections. Error bars are 95% CI for 
growth curves and minimum-maximum for other graphs.
Szablowski et al. Page 17
Mol Cancer Ther. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Treatment with 1 decreases tumor proliferation, induces apoptosis in HIF-1a positive 
areas and does not lead to HIF-1a accumulation
A) Regions used for local analysis in U251 tumors (Schedule B treatment). All analysis was 
done at 20× magnification, perinecrotic area contained 50% necrosis and 50% adjacent, non-
necrotic area, as shown. B) Treatment with 1, induced a modest, but statistically significant 
decrease in proliferative index (Ki-67 staining). C) The non-necrotic region exhibited low 
numbers of HIF-1a positive pixels. D) Perinecrotic area was more positive in HIF-1a. 
However, there were no differences in HIF-1a levels between the treatment groups. E) Cells 
in perinecrotic region show significant increase in CC3 staining upon treatment with 1. F) 
However, non-necrotic tumor regions show no presence of apoptosis. For each measurement 
n=10, per condition. Error bars denote minimum and maximum.
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Figure 4. Treatment with 1 increased reliance of tumor cells on proximity to vasculature
U251 cells with impaired adaptation to hypoxia are more sensitive to low oxygen pressures. 
Necrosis can form in the areas with inadequate oxygen supply, typically at a distance of ~ 
200 μm (oxygen diffusion limit in tissue) from blood vessels. As the oxygen pressure is 
dependent on the blood supply and necrosis is dependent on the oxygen pressure, the density 
of blood vessels around necrosis is an indirect, phenotypic, endpoint of hypoxic adaptation 
that is highly quantifiable. To measure the degree of hypoxic adaptation impairment upon 
the treatment with 1, necrosis was delineated manually and zones were offset every 50 μm. 
Number of blood vessels per area was calculated for each zone and converted to MVD. A) 
Group treated with 1 shows higher MVD in perinecrotic areas - within 150 and 200 μm from 
the edge of necrosis. B) Example of necrosis along with delineation and zonal analysis of 
MVD. (n=10 tumor per condition, 854 total microvessels measured for a group treated with 
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1 and 586 for a group treated with vehicle). Arrows denote two of the large microvessels, N 
denotes necrosis. Error bars denote 95% CI.
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Figure 5. Treatment with 1 inhibits transcription of proangiogenic and prometastatic factors in 
tumors
Mice harboring U251 tumors were treated according to Schedule D to capture gene 
expression profile underlying the changes in tumor mass and MVD (n=8 per condition). We 
registered a significant downregulation of several important proangiogenic factors (A), 
including Angiopoietins 1 and 2 (ANGPT1, ANGPT2), overall tumor levels of their receptor 
mouse-Tie-2 (Tek), Neuroligin 1 (NLGN1) as well as Platelet-Derived Growth Factor-B 
(PDGFB). Interestingly, both mRNA expression (B) and serum protein levels of a human-
VEGFA (C) were upregulated slightly in treated animals (n=8,6 for samples treated with 
vehicle and 1). We selected a panel of prometastatic factors and found that 1 inhibits mRNA 
expression in all tested transcripts except MMP2 (D). Error bars denote 95% CI.
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Figure 6. Treatment with 1 inhibits tumor growth and decreases density of vasculature without 
induction of HIF-1a or expression of proangiogenic factors
A) Compound 1 reduces microvessel density, hypoxia-related gene expression and cell 
proliferation, but does not increase HIF-1a levels. Presence of apoptosis in HIF-1a positive, 
but not HIF-1a negative areas, increased reliance of cancer cells on proximity to vasculature 
also indicate increased sensitivity of cancer cells to hypoxia. B) Therapies targeting 
angiogenesis that do not impair hypoxic adaptation (e.g. Anti-VEGF) can lead to increased 
expression of prometastatic and proangiogenic factors. Treatment with 1 inhibits expression 
of many of those factors, thus contributing to impaired adaptation of tumors to hypoxia.
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